Patents by Inventor Thomas J. Kelly

Thomas J. Kelly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210283099
    Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.
    Type: Application
    Filed: May 26, 2021
    Publication date: September 16, 2021
    Inventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
  • Publication number: 20210272476
    Abstract: A trainer for practicing an intraosseous infusion is presented. The trainer includes a mannequin and an injection-site simulant. The mannequin is in the form of a body, human or animal, in part or whole. The injection-site simulant further includes a pocket, an insert, and an outer cover. The pocket extends into the mannequin. The insert simulates a hard exterior of a bone. The insert is disposed within the pocket. The outer cover with a plug simulates a skin, human or animal. The outer cover conceals the insert, the pocket, and the plug. The pocket and the insert cooperate to form a cavity. The cavity is disposed where marrow resides within the bone. The cavity is capable of receiving a fluid injected through a hole formed during use through the outer cover, the plug, and the insert. The plug sealingly contacts and cooperates with at least one of the insert or the wall within the pocket to confine the fluid within the cavity.
    Type: Application
    Filed: May 7, 2021
    Publication date: September 2, 2021
    Inventors: Daniel J. Parry, David J. Parry, JR., Thomas D. Kelly
  • Patent number: 11045446
    Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: June 29, 2021
    Assignee: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
  • Publication number: 20190314329
    Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.
    Type: Application
    Filed: November 13, 2018
    Publication date: October 17, 2019
    Inventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
  • Patent number: 10372463
    Abstract: A technique provisions a computerized device with a main operating system. The technique involves loading, while the computerized device operates as a preboot execution environment (PXE) protocol client, a limited boot image from a PXE server over a network (e.g., booting the limited boot image using the trivial file transfer protocol or TFTP). The technique further involves executing the limited boot image loaded from the PXE server to operate the computerized device as an advanced protocol provisioned client. The technique further involves downloading, while the computerized device executes the limited boot image to operate as the advanced protocol provisioned client, the main operating system into local memory from an operating system server over the network (e.g., booting the main operating system using the file transfer protocol or FTP). The computerized device may store a copy of the main operating system in a local non-volatile cache if available.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: August 6, 2019
    Assignee: EMC IP Holding Company LLC
    Inventors: Kevin P. Twomey, Daniel J. Roche, Xiao Lou, Thomas J. Kelly, Isaias A. Barinas, Frank T. Smith
  • Patent number: 10123992
    Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: November 13, 2018
    Assignee: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
  • Patent number: 10062042
    Abstract: A technique assigns tasks to workers within a work area. The technique utilizes electronic circuitry which can be disposed at a single location (e.g., a server), or distributed among multiple locations (e.g., in the cloud). The technique involves receiving task entries which (i) identify tasks in need of attention and (ii) define task requirements for performing the tasks. The technique further involves generating task assignments based on matching the task entries to worker profiles which (i) identify workers who are available for task assignment and (ii) define worker characteristics of the workers. The technique further involves providing the task assignments to the workers while the workers are distributed among different locations within the work area. The task assignments direct the workers to perform the tasks identified by the task entries in accordance with the task requirements defined by the task entries.
    Type: Grant
    Filed: September 25, 2012
    Date of Patent: August 28, 2018
    Assignee: EMC IP Holding Company LLC
    Inventors: Thomas J. Kelly, John R. Carmody, Kevin P. Twomey, Frank T. Smith
  • Publication number: 20180125815
    Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.
    Type: Application
    Filed: October 10, 2017
    Publication date: May 10, 2018
    Applicant: Sloan-Kettering Institute for Cancer Research
    Inventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
  • Patent number: 9782386
    Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: October 10, 2017
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
  • Patent number: 9692656
    Abstract: A policy distribution server provides, on a subscription basis, policy updates to effect desired behaviors of network intermediary devices. The policy updates may specify caching policies, and may in some instances, include instructions for data collection by the network intermediary devices. Data collected in accordance with such instructions may be used to inform future policy updates distributed to the network intermediary devices.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: June 27, 2017
    Assignee: Symantec Corporation
    Inventors: Kevin Porter, Thomas J. Kelly, Marcin Lukasz Lizon, Darrell Long, Eric Maki, Kim Tremblay, Jennifer Vance
  • Publication number: 20170119731
    Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.
    Type: Application
    Filed: November 11, 2016
    Publication date: May 4, 2017
    Applicant: Sloan-Kettering Institute for Cancer Research
    Inventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
  • Patent number: 9492427
    Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: November 15, 2016
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
  • Publication number: 20160127189
    Abstract: A policy distribution server provides, on a subscription basis, policy updates to effect desired behaviors of network intermediary devices. The policy updates may specify caching policies, and may in some instances, include instructions for data collection by the network intermediary devices. Data collected in accordance with such instructions may be used to inform future policy updates distributed to the network intermediary devices.
    Type: Application
    Filed: January 8, 2016
    Publication date: May 5, 2016
    Inventors: Kevin Porter, Thomas J. Kelly, Marcin Lukasz Lizon, Darrell Long, Eric Maki, Kim Tremblay, Jennifer Vance
  • Publication number: 20160058733
    Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.
    Type: Application
    Filed: November 9, 2015
    Publication date: March 3, 2016
    Applicant: Sloan-Kettering Institute for Cancer Research
    Inventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
  • Patent number: 9237068
    Abstract: A policy distribution server provides, on a subscription basis, policy updates to effect desired behaviors of network intermediary devices. The policy updates may specify caching policies, and may in some instances, include instructions for data collection by the network intermediary devices. Data collected in accordance with such instructions may be used to inform future policy updates distributed to the network intermediary devices.
    Type: Grant
    Filed: January 30, 2011
    Date of Patent: January 12, 2016
    Assignee: Blue Coat Systems, Inc.
    Inventors: Kevin Porter, Thomas J. Kelly, Marcin Lukasz Lizon, Darrell Long, Eric Maki, Kim Tremblay, Jennifer Vance
  • Patent number: 9180105
    Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B) or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.
    Type: Grant
    Filed: March 8, 2011
    Date of Patent: November 10, 2015
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
  • Publication number: 20130035301
    Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B) or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.
    Type: Application
    Filed: March 8, 2011
    Publication date: February 7, 2013
    Applicant: Sloan-Kettering Institute for Cancer Research
    Inventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
  • Patent number: 8312264
    Abstract: A digital certificate associating a unique identifier for a computer-based appliance with an authentication key pair for that appliance is obtained from a certificate authority using a different, manufacturing key pair for the appliance. The manufacturing key pair may be generated by the appliance at or about its time of manufacture. The public key portion of the manufacturing key pair along with the unique identifier for the appliance may be provided via secure means to the certificate authority prior to the request for the digital certificate concerning the authentication key pair. Eventually, the digital certificate associated with the authentication key pair may be used by the appliance when joining a network, as part of a one-way or two-way authentication process.
    Type: Grant
    Filed: January 24, 2008
    Date of Patent: November 13, 2012
    Assignee: Blue Coat Systems, Inc.
    Inventors: Thomas J. Kelly, Ronald Frederick, Shrikrishna Karandikar, Wei Jen Yeh, Vineet Kumar
  • Patent number: 8301887
    Abstract: A first computer-based device is authenticated at a second computer-based device communicatively coupled thereto through use of a unique identifier and an encrypted token, each received from the first device. Following the authentication, configuration information for the first device is sent from the second device to the first device and the first device is authorized to join a network that includes the second device. Further, permissions related to the network may be granted to the first device.
    Type: Grant
    Filed: January 31, 2008
    Date of Patent: October 30, 2012
    Assignee: Blue Coat Systems, Inc.
    Inventors: Thomas J. Kelly, Samuel H. McLane, Ronald Frederick, Dharmendra Mohan, Darrell G. Long
  • Publication number: 20120198038
    Abstract: A policy distribution server provides, on a subscription basis, policy updates to effect desired behaviors of network intermediary devices. The policy updates may specify caching policies, and may in some instances, include instructions for data collection by the network intermediary devices. Data collected in accordance with such instructions may be used to inform future policy updates distributed to the network intermediary devices.
    Type: Application
    Filed: January 30, 2011
    Publication date: August 2, 2012
    Applicant: BLUE COAT SYSTEMS, INC.
    Inventors: Kevin Porter, Thomas J. Kelly, Marcin Lukasz Lizon, Darrell Long, Eric Maki, Kim Tremblay, Jennifer Vance